endpts.com Open in urlscan Pro
13.32.27.85  Public Scan

Form analysis
1 forms found in the DOM

https://endpts.com/

<form action="https://endpts.com/">
  <input type="text" name="s" placeholder="Search">
  <button class="epn_ux_button epn_white epn_search_submit_button"></button>
</form>

Text Content

 * Channels
   * All News
   * In Focus
   * Special
   * AI
   * Bioregnum
   * Biotech Voices
   * Cell/Gene Tx
   * China
   * Coronavirus
   * Deals
   * Diagnostics
   * Discovery
   * FDA+
   * Financing
   * Health Tech
   * Law
   * Letters to the Editor
   * Manufacturing
   * Marketing
   * Opinion
   * Outsourcing
   * Peer Review
   * People
   * Pharma
   * R&D
   * Startups
   * Weekly
 * Webinars
 * Biopharma Jobs
 * More
   * Work at Endpoints
   * Letter to Editors
   * IPO Tracker
   * Webinars
   * Events
   * Sponsored Posts
   * Advertise
   * Privacy Policy
   * Endpoints Merch
   * About Us
   * Help


 * SIGN UP
 * LOG IN



November 6, 2023 11:31 AM EST
News Briefing


ZEN­TAL­IS SHAKES UP PHI­II PLANS IN OVAR­I­AN CAN­CER; HALOZYME'S DEAL WITH
ACU­MEN; KO­R­RO'S $117M PRI­VATE PLACE­MENT


LEI LEI WU

NEWS REPORTER


JAIMY LEE

DEPUTY EDITOR

Zen­tal­is Phar­ma shakes up plans for Phase III in ovar­i­an can­cer:
Zen­tal­is an­nounced Mon­day that it is no longer plan­ning to test its lead
can­di­date, azenosert­ib, in com­bi­na­tion with chemother­a­py in sec­ond-line
plat­inum-sen­si­tive ovar­i­an can­cer (PSOC) pa­tients. The Phase III study
was ex­pect­ed to start in the first quar­ter of next year. In­stead, the
com­pa­ny plans to test the wee1 in­hibitor as a first-line main­te­nance
treat­ment for PSOC, push­ing back the time­line for be­gin­ning a Phase III
tri­al in­to 2025. Zen­tal­is al­so shared up­dat­ed re­sults from a Phase I
study in plat­inum-re­sis­tant ovar­i­an can­cer. The biotech is cur­rent­ly
run­ning a Phase II tri­al for which it plans to share topline da­ta in 2025.
Zen­tal­is {ZNTL} shares fell over 20% af­ter mar­kets opened Mon­day. — Lei Lei
Wu

Halozyme Ther­a­peu­tics’ new deal with Acu­men: The San Diego-based com­pa­ny
on Mon­day an­nounced a non-ex­clu­sive deal that pairs Halozyme’s
sub­cu­ta­neous drug de­liv­ery tech­nol­o­gy with Acu­men’s mon­o­clon­al
an­ti­body that is be­ing test­ed in ear­ly Alzheimer’s dis­ease. Fi­nan­cial
terms of the deal, which in­cludes an up­front, mile­stones and roy­al­ties,
were not dis­closed. — Jaimy Lee

advertisement

advertisement

Ko­r­ro Bio clos­es Fre­quen­cy deal, rais­es $117M: The bio­phar­ma said
Fri­day that its merg­er with Fre­quen­cy Ther­a­peu­tics closed. The com­bined
com­pa­ny is now trad­ing on the Nas­daq Cap­i­tal Mar­ket un­der the tick­er
“KR­RO.” It al­so com­plet­ed a $117 mil­lion pri­vate place­ment led by
Sur­vey­or Cap­i­tal and said it ex­pects its cash to last in­to 2026. Ko­r­ro’s
stock was up about 4% on Mon­day morn­ing. — Jaimy Lee




AUTHORS


LEI LEI WU

NEWS REPORTER

lwu@endpointsnews.com @leilei_wuu



JAIMY LEE

DEPUTY EDITOR

jlee@endpointsnews.com
Jaimy Lee on LinkedIn


TRENDING NOW


FDA RAIS­ES CON­CERNS OVER EF­FI­CA­CY OF MER­CK­'S PO­TEN­TIAL CHRON­IC COUGH
DRUG AHEAD OF AD­COMM


BACKED BY EX-GOOGLE CEO ER­IC SCHMIDT, A NEW NON­PROF­IT LOOKS TO 'SOLVE
SCI­ENCE' WITH AI


GILEAD­'S KITE DOU­BLES DOWN ON AR­CEL­LX'S BLOOD CAN­CER CELL THER­A­PIES WITH
$285M


MUR­AL ON­COL­O­GY SPINS OUT FROM ALK­ER­MES WITH $275M AND A LEAD
IM­MUNOTHER­A­PY PRO­GRAM


IS THE WORST OVER? CATAL­ENT TOUTS GLP-1 AND GENE THER­A­PY BUSI­NESS AS IT
STICKS TO FI­NAN­CIAL GUID­ANCE

sponsored


CLIN­I­CAL STUD­IES IN JAPAN TO­DAY: AN­OTH­ER LOOK AT THE WORLD’S
SEC­OND-LARGEST PRE­SCRIP­TION DRUG MAR­KET IN A ...


YOU HAVE READ 4 OUT OF YOUR 4 FREE MONTHLY ARTICLES. FOR UNLIMITED ACCESS,
UPGRADE TO A PREMIUM PLAN.

UPGRADE

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas




LATEST

 * All News
 * Special
 * In Focus
   


CHANNELS

 * AI
 * Bioregnum
 * Biotech Voices
 * Cell/Gene Tx
 * China
 * Coronavirus
 * Deals
 * Diagnostics
 * Discovery
 * FDA+
 * Financing
 * Health Tech
 * Law
 * Letters to the Editor
 * Manufacturing
 * Marketing
 * Opinion
 * Outsourcing
 * Peer Review
 * People
 * Pharma
 * R&D
 * Startups
 * Weekly


MORE

 * Work at Endpoints
 * Letter to Editors
 * IPO Tracker
 * Events
 * Webinars
 * Sponsored Posts
 * Advertise
 * Endpoints Merch
 * About Us
 * Help


WORK IN BIOTECH

 * Endpoints Careers

© Endpoints News 2023

 * Help
 * Advertise
 * Privacy Policy
 * Business Model




LOG IN TO YOUR ACCOUNT


EMAIL




PASSWORD


Change my password Get a magic email link
LOG IN


REQUEST MAGIC LINK

If you're already an Endpoints subscriber, enter your email below for a magic
link that lets you log in quickly without using a password. Please note the
magic link is one-time use only and expires after 24 hours.


EMAIL


BACK
REQUEST


RESET PASSWORD

We'll e-mail you a link to set a new password. Please note this link is one-time
use only and is valid for only 24 hours.


EMAIL


BACK
RESET

SIGN UP FOR FREE TO READ A LIMITED NUMBER OF ARTICLES EACH MONTH.

ABOUT YOU







NEWSLETTER INTERESTS

PICK WHAT NEWSLETTERS GET DELIVERED TO YOUR INBOX EACH WEEK.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET



EARLY EDITION Daily at 7:15 AM ET



ENDPOINTS PHARMA Daily at 2 PM ET



BREAKING NEWS ALERTS 2-3 times a week



ENDPOINTS MARKETING RX Tue at 2 PM ET



ENDPOINTS FDA+ Wed at 2 PM ET



ENDPOINTS MANUFACTURING Thu at 2 PM ET



ENDPOINTS WEEKLY Sat at 6 AM ET



Healthcare

ENDPOINTS HEALTH TECH Coming soon


INSTANT SIGN UP

Want unlimited access? Sign up for a premium subscription plan.